Professional
Added to YB: 2020-01-29
Pitch date: 2020-01-29
HRTX [bullish]
Heron Therapeutics, Inc.
-93.92%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Market Cap
$201.7M
Pitch Price
$22.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.18
P/E
-12.79
EV/Sales
1.90
Sector
Biotechnology
Category
growth
Show full summary:
Appleseed Fund holding: Heron Therapeutics (HRTX)
HRTX: Cinvanti reduces chemo nausea & allergies. HTX-011 local anesthetic may cut post-op opioid use 72hrs+. FDA "Breakthrough" status but approval delayed, stock -50% to $20. Bupivacaine is proven, delivery tech already in Sustol. Approval and opioid crisis solution expected.
Read full article (2 min)